Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer

• Published in: The New England journal of medicine Vol. 390; no. 14; pp. 1265 - 1276
• Main Authors: Wu, Yi-Long, Dziadziuszko, Rafal, Ahn, Jin Seok, Barlesi, Fabrice, Nishio, Makoto, Lee, Dae Ho, Lee, Jong-Seok, Zhong, Wenzhao, Horinouchi, Hidehito, Mao, Weimin, Hochmair, Maximilian, de Marinis, Filippo, Migliorino, M. Rita, Bondarenko, Igor, Lu, Shun, Wang, Qun, Ochi Lohmann, Tania, Xu, Tingting, Cardona, Andres, Ruf, Thorsten, Noe, Johannes, Solomon, Benjamin J.
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 11.04.2024
• Subjects: Administration, Intravenous; Administration, Oral; Antineoplastic Agents - therapeutic use; Cancer therapies; Carbazoles - therapeutic use; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - surgery; Central nervous system; Chemotherapy; Committees; Critical Care; Critical Care General; Drug dosages; Drug withdrawal; Hematology; Humans; Immunotherapy; Kinases; Lung Cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - surgery; Magnetic resonance imaging; Neoplasm Recurrence, Local - drug therapy; Non-small cell lung carcinoma; Oncology; Piperidines - therapeutic use; Platinum; Platinum Compounds - therapeutic use; Pulmonary; Receptor Protein-Tyrosine Kinases; Safety; Small cell lung carcinoma; Statistical analysis; Thoracic surgery; Treatment Outcome; Treatments in Oncology; Tyrosine Kinase Inhibitors - therapeutic use
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa2310532

In a trial of adjuvant treatment for patients with resected ALK -positive non–small-cell lung cancer, disease-free survival at 2 years was 93.6% with the ALK inhibitor alectinib and 63.7% with standard chemotherapy.